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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYThe use of cells derived from pluripotent stem cells (PSCs) for regenerative therapies confers a considerable risk for neoplastic growth and
teratoma formation. Preclinical and clinical assessment of such therapies will require suitable monitoring strategies to understand and
mitigate these risks. Here we generated human-induced pluripotent stem cells (iPSCs), selected clones that continued to express reprog-
ramming factors after differentiation into cardiomyocytes, and transplanted these cardiomyocytes into immunocompromised rat hearts
post-myocardial infarction.We comparedmagnetic resonance imaging (MRI), cardiac ultrasound, and serum biomarkers for their ability
to delineate teratoma formation and growth. MRI enabled the detection of teratomas with a volume >8 mm3. A combination of three
plasma biomarkers (CEA, AFP, and HCG) was able to detect teratomas with a volume >17 mm3 and with a sensitivity of more than
87%. Based on our findings, a combination of serum biomarkers withMRI screeningmay offer the highest sensitivity for teratoma detec-
tion and tracking.INTRODUCTION
The loss of cardiomyocytes following myocardial infarc-
tion (MI) leads to reduced force generation that may
culminate in heart failure and death (Jessup and Brozena,
2003). Without effective treatment options available
to restore lost myocytes, emerging regenerative cell
therapies have gained interest. Recent advances in our
ability to derive and expand pluripotent stem cells
(PSCs) as well as to differentiate them to different cell
types such as cardiomyocytes have raised hopes that these
cells might be able to replace cells lost during injury or
disease and restore organ function (Burridge et al., 2012,
2014).
Preclinical and clinical studies have demonstrated that
embryonic stem cell-derived cardiomyocytes (ESC-CMs)
or induced PSC-derived cardiomyocytes (iPSC-CMs) alone
or as cell sheets can engraft in recipient hearts and improve
cardiac function (Caspi et al., 2007; Laflamme et al., 2007;
Riegler et al., 2015; van Laake et al., 2007). These and other
encouraging findings have led to an increased effort to
investigate the safety of ESC-CMs and iPSC-CMs in preclin-
ical animal models and in phase I clinical trials (Menasche
et al., 2015). The safety of adult stem cell transplantation176 Stem Cell Reports j Vol. 6 j 176–187 j February 9, 2016 j ª2016 The Auinto the heart (primarily bonemarrow cells) has been estab-
lished, but to date functional improvements have been
underwhelming (Fisher et al., 2014).
In contrast to bonemarrow cells and other adult stem cell
populations with limited growth and differentiation po-
tential, ESCs and iPSCs have unlimited growth and
differentiation potential due to their pluripotent nature
(Takahashi and Yamanaka, 2006; Thomson et al., 1998).
However, transplantation and engraftment of undifferenti-
ated PSCs can lead to the formation of teratomas, which are
typically benign neoplastic growths comprised of tissues
from all three germ layers (Ben-David and Benvenisty,
2011; Lee et al., 2013). Hence, it is highly unlikely that
ESCs or iPSCs would be used clinically without prior differ-
entiation to a specific cell type (e.g., cardiomyocytes, oligo-
dendrocytes, retinal pigment epithelium). Differentiation
limits the proliferative potential of PSCs, but contamina-
tion of differentiated cells with undifferentiated or partially
differentiated cells still poses amajor risk factor for inadver-
tent tumor or teratoma formation. In addition, there is
the possibility that cells might acquire mutations during
cultivation or de-differentiate following transplantation
(Baker et al., 2007; Mayshar et al., 2010). Since several
groups around the world are initiating clinical trials usingthors
Figure 1. Human iPSC-Derived Cardiomyocytes Showed a
Normal Phenotype but Continued to Express Pluripotency
Markers
(A) Confocal microscopy image of lentiviral-derived iPSC (clone T)-
generated cardiomyocytes (T-CMs) illustrating that differentiated
cells consisting primarily of cardiomyocytes with normal sarcomeric
structure. CTNT, cardiac troponin T; SAC, sarcomeric alpha actinin.
(B–E) Although cells were clearly expressing cardiac markers (CTNT;
b-myosin heavy chain [MYHC]), a substantial number of T-CMs
continued to express pluripotency markers OCT3/4, SOX2, and
NANOG as well as the cell-cycle gene C-MYC.
(F) Real-time PCR confirmed the overexpression of pluripotency
markers in the selected lentiviral-derived T-CMs in contrast to
control cardiomyocytes from a lentiviral-derived iPSC clone (C1) or
Sendai virus-derived clone (C2) (mean ± SD, n=3 independent
differentiations lots for each cell line).
Scale bars represent 50 mm.PSC-derived cells (Garber, 2013; Neofytou et al., 2015),
there is an urgent need to establish suitable monitoring
strategies to enable early detection of neoplastic growth
or teratoma formation. Ideally, such a monitoring strategy
should be non-invasive and should not require geneticStem Cemodification of the cell product. Since naturally occurring
teratomas in humans are rare, little is known about the
detection limit of different imaging modalities or serum
biomarkers that can aid in the early identification of
neoplastic growth or teratoma formation.
To address this bottleneck, we identified a human lentivi-
ral-derived iPSC clone that continued to express reprog-
ramming factors following differentiation, predisposing
cells from this clone to revert to a pluripotent state and
leading to efficient teratoma formation. We transplanted
iPSC-CMs from this line into rat hearts 4 days after MI. In
order to detect and track teratoma growth, MRI and ultra-
sound imaging combined with serial plasma collections
were performed every other week for 2 months. We tested
eight serumbiomarkers (carcinoembryonic antigen, a-feto-
protein, fibroblast growth factor, chorionic gonadotropin,
vascular endothelial growth factor, lactate dehydrogenase,
alkaline phosphatase, and cancer antigen-125) as well as
cancer protein and microRNA arrays for their ability to
detect teratomas and analyzed their correlations with tera-
toma size. Finally, we verified underlying MRI spin-lattice
and spin-spin relaxation rates by acquiring parametric
maps and characterized teratomas histologically.RESULTS
Lentiviral-Derived iPSC-CMs Continued to Express
Pluripotency Markers
Lentiviral-based gene delivery can lead to random integra-
tion of delivered genes, which may cause continued over-
expression or reactivation of reprogramming factors. Such
cell lines can be tumorigenic in vivo. We generated several
lentiviral iPSC clones, differentiated them to cardiomyo-
cytes, and selected a clone that continued to express re-
programming genes due to random integration (clone T)
and a control lentiviral clone that did not (clone C1). In
addition, we used non-integrating Sendai virus-based re-
programming to generate a second control line (clone
C2). None of the cell lines differed in their ability to
generate cardiomyocytes with high yields (>80%, n = 3,
Table S1). Cardiomyocytes from lentiviral clone T
(T-CMs) displayed normal sarcomeric organization, but
surprisingly some of the CMs continued to express
OCT3/4, SOX2, and NANOG, while almost all CMs were
positive for C-MYC (Figures 1A–1E). Gross examination
for aneuploidies via G-band karyotyping did not reveal
any abnormalities (data not shown). Substantial overex-
pression of pluripotency genes in CMs from line T was
confirmed by real-time PCR (Figure 1F). We also stained
T-CMs and C2-iPSCs for stage-specific embryonic antigen
4 (SSEA4) that could not be detected on T-CMs (data not
shown). Additional images depicting CMs stained forll Reports j Vol. 6 j 176–187 j February 9, 2016 j ª2016 The Authors 177
Figure 2. Serial MRI Using T2w, T2*w, and LGE Showed the Appearance and Continued Growth of Teratomas
(A) Representative T2w images of a rat heart 1 day prior and 2, 4, 6, and 8 weeks after cell delivery. A small teratoma with short relaxation
times in the core surrounded by a hyperintense rim could be seen from week 2 onward.
(B) T2*w images for the same teratoma showed a small teratoma 2 weeks after cell injection surrounded by hypointense voxels in the rim.
This hypointense rim was gradually pushed outward as the teratoma continued to grow.
(C) LGE images depicted increased left ventricular wall thickness from week 2 onward with hyperintense areas containing non-enhanced
clusters illustrating the internal heterogeneity of teratomas.
Dashed red lines outline approximate teratoma boundaries. Scale bars represent 5 mm.pluripotency markers from both T and C2 lines can be
found in Figure S1.
T2-Weigthed, T2*-Weighted, and Delayed
Enhancement MRI Enabled Teratoma Detection 2
Weeks after Cell Delivery
Little is known about detection limits and the suitability of
different imaging sequences for tracking of teratomas that
might arise in the heart after cell therapy. To address this,
we induced MI in rats by occluding the left anterior de-
scending coronary artery for 1 hr followed by reperfusion.
Each animal had a baselineMRI and ultrasound 3 days after
MI and received an intramyocardial injection of 1 3 107
T-CMs a day later. Following cell delivery, rats were imaged
every 2 weeks for 2 months.
We were able to detect teratomas as soon as 2 weeks after
cell delivery on T2-weighted images (T2w). Teratomas pre-
sented as hyperintense regions with a hypointense rim.
Serial imaging showed continued growth of teratomas (Fig-
ure 2A). On T2*-weighted images (T2*w), teratomas could
be primarily discerned by a hypointense core appearing
early after cell delivery that persisted as a hypointense178 Stem Cell Reports j Vol. 6 j 176–187 j February 9, 2016 j ª2016 The Aurim as the mass continued to grow (Figure 2B). Teratoma
appearance on late gadolinium enhancement images
(LGE) was slightly more varied. Small masses typically pre-
sented as hyperintense regions. However, as masses
continued to grow, contrast enhancement declined and
small clusters with enhancement rates close to normal
myocardium appeared, indicating high cell densities (Fig-
ure 2C). Teratomas could be detected only indirectly on
T1-weighted images (T1w) or gradient echo cine images
via increased myocardial wall thickness compared with
baseline scans (Figures S2A–S2C). In contrast, the low
signal to noise ratio of ultrasound images made the detec-
tion of masses more difficult. But unusual structures in
the myocardial wall or lumen could be detected once tera-
tomas had reached a sufficient size (>50 mm3; Figure S2D).
Imaging at later time points illustrated the ability to detect
teratoma spreading to the surrounding lung tissue (Figures
S2E and S2F). We next performed T1, T2, and T2* mapping
on explanted hearts to verify underlying relaxation
rates responsible for teratoma appearance with different
contrast weighting (Figure S3). T2 mapping confirmed
long relaxation times for teratoma cores surrounded withthors
Figure 3. Teratoma Volume Estimates from Different MRI
Sequences Were Comparable
(A) Teratoma volume estimates from LGE images showed similar
exponential growth for different animals receiving T-CMs (n = 5
rats).
(B) Bland-Altman plot for teratoma volume estimated from LGE and
T1w images (n = 5 rats, 4 time points) showed a systematically
lower volume estimate for T1w images (10 mm3) and an SD of
16 mm3.
(C and D) Bland-Altman plots for T2w and T2*w imaging (n = 5
rats, 4 time points) showed little offset between LGE and T2w or
T2*w volume estimates (1 and 4 mm3, respectively). SDs for
the differences between LGE and T2w or T2*w volume estimates
(n = 5 rats, 4 time points) were also similar (18 and 17 mm3,
respectively).a rim exhibiting short relaxation times compared to
normal myocardium (core, 49 ± 8 ms; rim, 30 ± 3 ms;
normal, 38 ± 2 ms; n = 3 hearts). Short relaxation times
of the teratoma rim were even more pronounced on T2*
maps (rim, 14 ± 1 ms; normal, 35 ± 5 ms; Table S2).
Teratoma VolumesWere Similar for Different Imaging
Sequences
Teratoma volumes were measured via manual segmenta-
tion by a blinded observer to assess detection limits and
limits of agreement for volume estimates based on different
imaging sequences. LGE enabled the detection of tera-
tomas >7 mm3 and showed exponential growth with
similar growth rates for all five teratomas in this experi-
ment (Figure 3A). Volume estimates from T1w images
were systematically lower (10 mm3) compared with LGE
(Figure 3B). Teratoma volumes from T2w and T2*w imaging
had small systematic differences (1 and +4 mm3, respec-
tively) and a similar variability when compared againstStem CeLGE (Figures 3C and 3D). A log-linear plot confirmed expo-
nential growth (R2 = 0.87) with a 10-day doubling time for
teratoma volume (n = 5).
Cardiac Function Was Not Affected by Teratoma
Growth or Transplantation of Human
Cardiomyocytes
Blinded cine data were analyzed to measure potential
changes in cardiac function due to teratoma growth. Five
out of eight rats that received T-CMs developed teratomas.
Histological analysis of hearts from the three animals
without cardiac teratomas showed no significant engraft-
ment of human cells in these hearts (screening sections
every 360 mm). We did not observe any statistically signifi-
cant differences in left ventricular end-diastolic volume
(p = 0.27), left ventricular end-systolic volume (p = 0.45),
or left ventricular ejection fraction (p = 0.72) between
hearts with teratomas and hearts without cell engraftment
(Figure S4 and Table S3).
In order to evaluate functional benefits from the trans-
plantation of human iPSC-CMs into ischemic rat hearts,
C1-CMs (no integration, n = 12) or PBS (n = 12) were in-
jected into the border zone of the injured myocardium
4 days after ischemia reperfusion. Follow-up cardiac MRI
4 weeks after baseline imaging and cell transplantation
did not detect any significant differences in left ventricular
end-diastolic volume (p = 0.11), left ventricular end-sys-
tolic volume (p = 0.14), or left ventricular ejection fraction
(p = 0.68) between the PBS and C1-CM transplantation
groups (Table S4).
Serum Biomarkers Were Able to Detect Teratomas 4
Weeks after Cell Delivery
We tested plasma collected at each imaging time point
(0, 2, 4, 6, 8 weeks after cell delivery) for biomarkers
associated with germ cell tumors or general tumors. We
found that a combination of two biomarkers, carcinoem-
bryonic antigen (CEA) andhuman chorionic gonadotropin
(HCG), enabled the detection of 87% (7/8) of teratomas
once teratomas had reached a volume>40mm3 (Figure 4A).
The addition of a third biomarker, a-fetoprotein (AFP),
improved the detection limit for AFP-positive teratomas
to >17 mm3. The ability of single biomarkers to detect ter-
atomas were as follows: CEA, 75% (6/8); AFP, 50% (4/8);
fibroblast growth factor (FGF), 50% (4/8); HCG, 25%
(2/8); and CA-125, 25% (2/8). Although there were slight
differences in the sensitivity of different biomarkers, their
detection limits were between 20 and 50 mm3. There was
considerable heterogeneity between teratomas with some
positive for four biomarkers, while others were only posi-
tive for one biomarker. We also observed one teratoma
(#449) that was negative for all biomarkers tested, despite
reaching a size of 70 mm3. In contrast, all of thesell Reports j Vol. 6 j 176–187 j February 9, 2016 j ª2016 The Authors 179
Figure 4. Plasma Biomarkers Were Able to Detect Most Tera-
tomas
(A) Heatmap depicting the volume equivalent radius of eight ter-
atomas 2 months after cell transplantation as well as corresponding
plasma levels for a range of biomarkers (n = 8 rats). All of the tested
biomarkers were below the detection limit for animals that received
either control CMs (H7-derived ESC-CMs, n = 9 rats, asterisk next to
animal number) or a subset of T-CMs that had failed to engraft and
form a teratoma (n = 5 rats). Teratoma radii are depicted on a linear
scale while plasma concentrations are depicted on a log scale.
(B) A weak correlation was found between CEA plasma levels and
teratoma volume estimates form LGE MRI (R2 = 0.23, n = 6 rats, 3
time points).
(C) Plasma levels of AFP were also weakly correlated with teratoma
volumes (R2 = 0.29, n = 4, 3 time points).
(D) Although AFP could be detected from some teratomas with a
volume of less than 20 mm3, it could not be detected before week 4
following cell delivery (n = 4 rats). Only one of three teratomas for
which >3 positive measurements were available showed AFP in-
creases reflecting teratoma growth. VEGF, vascular endothelial
growth factor.biomarkers were below the detection limit for 14 negative
control animals. These consisted of five samples from
rats where T-CMs failed to engraft (day 30 after cell deliv-
ery) and nine samples from rats with confirmed human
H7-derived ESC-CM grafts (days 30–190 after cell delivery,
Figures S5A–S5F). In addition, we observed loose correla-
tions between CEA or AFP levels and teratoma volumes
(R2 = 0.23, R2 = 0.29, Figures 4B and 4C). This was also
observed for some animals where biomarker levels
increased over time (Figure 4D).
Alternative Serum Biomarkers for Teratoma Detection
An additional set of T-CMswere transplanted into ischemic
rat hearts (n = 8) 4 days after ischemia reperfusion injury,180 Stem Cell Reports j Vol. 6 j 176–187 j February 9, 2016 j ª2016 The Aufollowed by plasma collection every other week and MRI
at 4 and 8 weeks after cell delivery. Plasma from four ani-
mals that developed teratoma was used to screen for
cancer-associated microRNAs or proteins. We were able to
detect two proteins, enolase-2 and angiopoietin-1, which
showed consistent concentration increases over time in
three out of four animals with confirmed teratomas (Fig-
ure S5G). In addition, we found four microRNAs (LET-7,
MIR-100, MIR-125, and MIR-126) that showed statistically
significant increases 8 weeks after cell transplantation
compared to baseline (Figure S5H, p < 0.05).
Late Gadolinium Enhancement Acquisitions Were
Sufficient for Teratoma Detection
Wenext set out to assess if LGE alone could be sufficient for
teratoma detection in an independent group of animals
(n = 16). Blinded analysis of LGE images 1 month after
cell delivery identified nine teratomas with 4–57 mm3 in
size. In hearts classified as teratoma free by MRI, histologi-
cal analysis confirmed the lack of human cell engraftment
or teratoma formation. Analysis of hearts with suspected
teratomas confirmed all teratomas with volumes >8 mm3
(Figure 5). However, one heart with a suspected teratoma
of 4 mm3 based on LGE was found to be teratoma free
when H&E stainings were analyzed. Taken together, these
results indicate that teratomas >8 mm3 can be detected
with LGE based on a voxel size of 0.04 mm3.
Teratomas Were Poorly Vascularized, Inflamed on the
Rim, and Contained Undifferentiated Cells
Immediately after the last imaging session (2 months after
cell delivery), hearts were harvested and sectioned for his-
tological examination. H&E staining revealed the presence
of undifferentiated cells, endodermal tissue, and some
mesodermal tissue as well as areas of necrosis in the core
of teratomas (Figures 6A, 6B, S6A, and S6B). We also
observed a substantial number of hemosiderin-laden mac-
rophages along the rim of teratomas. Prussian blue staining
confirmed that these macrophages contained a substantial
amount of iron (Figures 6C, 6D, S6C, and S6D). Closer in-
spection of teratoma #449, which tested negative for all
biomarkers, revealed substantial necrosis within the core
as well as the presence of undifferentiated cells with the
absence of endodermal or ectodermal tissues and gland-
like structures (Figure S6B). KI67 immunofluorescence
staining confirmed that the majority of human cells were
in an active state of the cell cycle (Figures 6E and S6E), in
line with the observed exponential growth rates. Acute
and chronic inflammation along the teratoma rim was
confirmed by macrophage accumulation. However, only
a few macrophages were found inside human cell clusters
(Figures 6F and S6F). Although the myocardium is highly
vascularized, teratomas contained few blood vessels andthors
Figure 5. Teratomas Displayed Spatial Heterogeneity on LGE
Images
(A–D) LGE images showing a small and a large teratoma 4 weeks
after cell delivery. Corresponding H&E images depicting the same
teratoma are shown on the right (n = 2 representative hearts of 8).
Teratomas are encircled with dashed lines.
(E and F) Teratomas continued to grow and led to spherical
displacement of the myocardial wall at day 75 after cell delivery
(n = 1 representative heart of 3). Small teratomas contained pri-
marily hyperintense voxels while larger teratomas contained some
hyperintense voxels and a large number of voxels that had a T1
relaxation time close to normal myocardium.
Scale bars represent 5 mm.only a small number of them were surrounded by smooth
muscle cells (Figures 6G, 6H, S6G, and S6H). We also
observed human cells staining positive for platelet endo-
thelial cell adhesion molecule (PECAM) marker without
showing vascular morphology. These cells are likely to be
stem cells since PECAM expression has been reported
previously for ESCs (Figure S6G). Immunofluorescence
staining confirmed the presence of undifferentiated cellsStem Ceexpressing the pluripotency markers OCT3/4 and SOX2
(Figures 6I, 6J, S6I, and S6J). Although T-iPSCswere initially
differentiated to cardiomyocytes and mesodermal tissue
was found in teratomas, we did not find significant human
cardiomyocytes within teratomas (data not shown). A large
number of cells staining positive for the endodermal
marker forkhead box protein A2 (FOXA2) was found in
all teratomas, with some also containing gland-like struc-
tures consisting of cells that contained AFP (Figures 6K
and S6K). Small clusters of human cells staining positive
for the ectodermal markers, neuron-specific class III beta-
tubulin (TUJ-1) and glial fibrillary acidic protein (GFAP),
were found in most teratomas (Figure 6L). While these ter-
atomas were relatively small and immature, the presence of
cells from all three germ layers could be confirmed. In
contrast to spontaneously accruing immature human tera-
tomas, our teratomas were lacking neuroepithelial tissues.DISCUSSION
Pluripotent stem cells offer unprecedented potential for
regenerative medicine as they can be differentiated by a
specific sequence of signals to become any cell type of the
body. At the same time, any cell product generated from
them confers a substantial risk for neoplastic growth or
teratoma formation (Cunningham et al., 2012). This risk
may come from contamination with undifferentiated cells,
culture-acquired mutations, or de-differentiation of cells
following transplantation (Baker et al., 2007; Lee et al.,
2013; Mayshar et al., 2010). While several studies have
been undertaken to determine the required number of
pluripotent cells in a cell preparation needed to cause tera-
toma formation (Cao et al., 2007; Lee et al., 2009; Nuss-
baum et al., 2007), little is known about the sensitivity of
potential imaging or serum biomarkers for teratoma detec-
tion following cell transplantation.
First-generation iPSC lines were made using lentivirus-
based reprogramming due to their efficiency (Takahashi
and Yamanaka, 2006). However, the risk for random inte-
gration of delivered genes is well known and led to the
eventual development of non-integrative reprogramming
methods (Aoi et al., 2008; Fusaki et al., 2009). Here
we generated a lentiviral-based iPSC line (line T) that
continued to express reprogramming factors after differen-
tiation. We reasoned that line T would be an appropriate
model for a cell product contaminated with pluripotent
cells or for cells with culture-acquired oncogenic transfor-
mations. The transcription factors used to induce pluripo-
tency aremaster regulators of cell states and are accordingly
strictly regulated and normally silenced during develop-
ment (Jaenisch and Young, 2008). Standard safety
screening of any cell product derived from pluripotent cellsll Reports j Vol. 6 j 176–187 j February 9, 2016 j ª2016 The Authors 181
Figure 6. Teratomas Were Highly Proliferative, Inflamed on the Rim, Poorly Vascularized, and Retained Pluripotent Cells
(A and B) H&E images of two teratomas 56 days after cell transplantation. Most teratomas contained primarily endoderm, some mesoderm,
and undifferentiated cells with necrosis in the core (n = 5 rats). Extensive formation of glands with endodermal appearance was also
observed. The teratoma from animal #449 (B) contained primarily undifferentiated cells, some mesoderm, and a necrotic core.
(C and D) All teratomas were surrounded by hemosiderin-laden macrophages (D, black arrows) along the margin (n = 5 rats). Prussian blue
(PB) staining confirmed the presence of iron-rich hemosiderin.
(E) A substantial number of human cells (human b1 integrin [B-INT]) were in an active state of the cell cycle (KI67) in line with the
proliferative nature of these teratomas.
(F) Chronic inflammation with macrophage accumulation (CD68) along the rim, but few macrophages infiltrating human cell clusters, was
observed.
(G) In contrast to highly vascularized (CD31) myocardial tissue, teratomas were poorly vascularized. Teratomas contained clusters of stem
cells staining positive for platelet endothelial cell adhesion molecule (CD31).
(H) Small arteries surrounded by smooth muscle cells (SM22) were abundant in normal myocardium, but few of these were observed in
teratomas. SM22 positive, fibroblast-like cells were observed surrounding human cell clusters. We also observed some human cells staining
positive for the mesodermal marker SM22.
(I and J) Teratomas contained human cell clusters (human mitochondria [H-MITO]) staining positive for pluripotency markers OCT-3/4
and SOX-2.
(K) A large number of human cells stained positive for the endodermal transcription factor forkhead box protein A2 (FOXA2). Gland-like
structures containing AFP-positive cells (endoderm) were found in most teratomas.
(L) Small cell clusters staining positive for the ectodermal markers neuron-specific class III beta-tubulin (TUJ-1) and glial fibrillary acidic
protein (GFAP) were observed in most teratomas.
Scale bars represent (A) 500 mm, (B, E–L) 100 mm, (C, D) 50 mm.will include expression analysis of pluripotency genes;
such a screen did easily detect the presence of pluripotent
cells in our T-CMs. However, if only a small population ex-
presses these genes or if expression is transiently repressed,182 Stem Cell Reports j Vol. 6 j 176–187 j February 9, 2016 j ª2016 The Audetection will become much more difficult. While the risk
of aberrant expression of reprogramming factors will be
much smaller for iPSC lines generated by non-integrative
methods, the risk for contamination of a cell productthors
with undifferentiated cells or de-differentiation will
remain. Current in vitro screening methods can detect
down to 1 undifferentiated cell in 100,000 differentiated
cells (Tano et al., 2014). Given that regenerative cell thera-
pies for MI may administer up to one billion cells (Chong
et al., 2014) and preclinical studies indicate that
1 3 104 to 1 3 105 cells are sufficient to induce teratoma
growth (Lee et al., 2009), current procedures for cell purifi-
cation and characterization cannot ensure that the cell
product is free of undifferentiated cells. With limited data
on ESC and iPSC-based cell therapies, the clinical risk for
teratoma formation is currently unknown. However, the
risk for tumor growth from stem cells has been highlighted
previously by a patient who developed a brain tumor after a
controversial non-US Food andDrug Administration (FDA)
approved neuronal stem cell transplantation (Amariglio
et al., 2009).
Clinical trials designed to assess the efficacy and safety
profile of cardiomyocytes derived from pluripotent cell
sources are likely to involve imaging modalities such as
MRI or ultrasound to assess cardiac function (Menasche
et al., 2015). We therefore decided to assess the suitability
of these modalities for safety screening. We were able to
detect neoplastic growth (teratoma) reliably using T2w im-
aging and LGE once masses had reached a volume of
8 mm3. Although this sensitivity will decrease with the
lower resolution of clinical MRI systems, it is likely to be
much lower than average teratoma sizes at the time of
detection currently reported (Chang and Lin, 2014; Cole-
man et al., 2014). Bland-Altman plots showed no system-
atic offset for teratoma volume estimates based on T2w
imaging or LGE. LGE might be particularly convenient
for potential teratoma or neoplastic growth detection since
it is frequently included in clinical studies to assess changes
in scar size (infarct size). Teratomas were poorly vascular-
ized and surrounded by a hypointense rim on T2w and
T2*w images. This easy detectable feature was caused
by hemorrhage around the teratoma leading to hemo-
siderin accumulation, which we confirmed histologically.
Although short T2 values have been described previously
for human ovarian teratomas, these were primarily due to
the formation of bone or fat tissues in mature teratomas
(Saba et al., 2009).
Cardiac MRI was performed to assess potential changes
in cardiac function due to teratoma growth. For this, a sub-
acute model with cell delivery 4 days after ischemia reper-
fusion injury was chosen since functional improvements
following the transplantation of human ESC-CMs have
been reported for this model (Laflamme et al., 2007).
T-CM transplantation leading to teratoma growth did not
cause statistically significant impairments or improve-
ments in function at our 2-month time point. This might
be attributable to still relatively small teratoma sizesStem Ce(average 76 ± 29 mm3) at our latest imaging time point.
The same animal model was used for a control group that
received PBS injections and for C1-CM (no integration of
reprogramming factors) transplantations. Follow-up MRI
4 weeks after cell delivery did not detect any functional
benefits from C1-CM transplantation in this model. This
lack of functional improvements might be due to differ-
ences in the animal surgical model, cell preparation, or
cell source used.
We were also able to detect teratomas using ultrasound
once they had reached a size of 50 mm3 at 6–8 weeks after
cell delivery. The lower sensitivity of ultrasound compared
with MRI is consistent with the literature for other organs
such as breast (Warner et al., 2001) or liver (Forner et al.,
2008), and is likely even more pronounced for the heart
where depth penetration and a restricted ultrasound win-
dowwill further limit accurate detection. Positron emission
tomography (PET) or single photon emission computed to-
mography (SPECT) imagingwould offer a higher sensitivity
compared toMRI (Nguyen et al., 2014) when specific radio-
tracers such as arginine-glycine-aspartic acid (RGD) peptide
agents, which target angiogenesis, are used (Cao et al.,
2009). Another advantage of PET and SPECT is the ability
to cover the entire body during an imaging session,
whereas MRI typically covers a smaller region such as the
head or chest. However, a potential disadvantage is the
repeated radiation exposure involving both PETand SPECT
radiotracers.
Serumor plasma biomarkers would be preferable over im-
aging biomarkers because they can be measured more
frequently, are more cost effective, and integrate informa-
tion from thewhole body.We chose to assess a range of bio-
markers that have been previously associated with germ
cell tumors (Polanski and Anderson, 2007). A combination
of three biomarkers (CEA, AFP, andHCG) was able to detect
87% (7/8) of teratomas with volumes >17 mm3. CEA and
AFP are both FDA approved as tumor-associated antigens.
CEA is a re-expressed oncofetal protein with a sensitivity
and specificity of 36% and 87%, respectively, for colorectal
cancer (Fletcher, 1986). It is currently used to detect recur-
rent colorectal cancer and liver metastasis. AFP is an onco-
fetal protein found in hepatocellular cancer, cirrhosis, and
hepatitis. Its sensitivity and specificity for hepatocellular
carcinoma are 50% and 70%, respectively (De Masi et al.,
2005). HCG is hormone produced during pregnancy and
has also been found in choriocarcinoma, testicular cancer,
and germ cell tumors. Elevated serum levels are found in
30% of patients with seminoma (a form of testicular can-
cer), 23% with renal cancer, and 10% with prostate cancer
among other types of cancer (Stenman et al., 2004).
FGF, which was able to detect 50% of teratomas in our
study, is a growth factor with mitogenic, angiogenic, and
neutrotrophic properties. FGF is frequently elevated inll Reports j Vol. 6 j 176–187 j February 9, 2016 j ª2016 The Authors 183
melanoma, glioma, and some other cancers. It is consid-
ered to be an important factor for tumor angiogenesis
and is therefore associated with tumor growth and malig-
nancy (Takahashi et al., 1992). Tumor detection sensitiv-
ities of individual serum biomarkers are typically low.
Combining several biomarkers can improve the sensitivity
to levels suitable for screening. This will be important for
teratomas that contain different amounts of tissues from
endoderm, mesoderm, or ectoderm, secreting distinct pro-
teins. Finally, we performed exploratory studies for addi-
tional novel biomarkers thatmight be suitable for teratoma
detection. We found four microRNAs (LET-7, MIR-100,
MIR-125, and MIR-126) that could detect teratomas and
had previously been associated with oncogenic transfor-
mations (Gu et al., 2015; Wu et al., 2015). Furthermore,
two proteins (enolase-2 and angiopoietin-1) that had
been previously associated with cancer and angiogenesis
(Song et al., 2014; Yu et al., 2001) showed increased plasma
concentrations that correlated with teratoma growth.
Additional research will be required to verify the detection
sensitivity of these potential biomarkers.Whilemore sensi-
tive biomarkers would be desirable, they would require
some time to be developed for clinical applications and to
be approved by US and European regulatory agencies.
Small or immature teratomas are particularly hard to
detect due to the lack of tissues with high secretion levels
such as gland-like structures. In line with that, we found
one teratoma in our test set for which none of the eight
tested biomarkers was positive. Histological characteriza-
tion showed that this particular teratoma had substantial
necrosis in the core, did not contain any gland-like struc-
tures, and consisted primarily of undifferentiated cells.
Immature teratoma will therefore limit the sensitivity of
serum biomarkers for early teratoma detection unless a
new sensitive biomarker for undifferentiated cells can be
found (Ahrlund-Richter and Hendrix, 2014). However,
they are likely to be detectable by imaging as this immature
teratoma was readily detectable via MRI. Furthermore,
screening strategies for regenerative cell therapies should
also be able to detect neoplastic growth that might be diffi-
cult to detect with serum biomarkers depending on the cell
types that are growing. A combination of serumbiomarkers
and structural imaging should offer a high probability to
detect neoplastic growth, as well as immature and mature
teratomas. Although detection limits from small-animal
studies are difficult to extrapolate to human scale, the
larger plasma volume and lower imaging resolution of clin-
ical MRI systems will decrease the sensitivity to detect
teratoma. Assuming a similar growth rate for teratomas in
humans and a linear decrease in detection sensitivity corre-
sponding to increased plasma volume and decreased image
resolution, blood sampling and imaging frequencies could
be reduced for humans (Figure S6M).We observed a growth184 Stem Cell Reports j Vol. 6 j 176–187 j February 9, 2016 j ª2016 The Aurate of 10 days for the doubling of teratoma volume, which
is similar to high growth rates of 11–12 days that have been
observed for some human teratomas (Selby et al., 1979).
Even with such a high growth rate, it would take several
months for a teratoma to reach detection limits in humans
as the number of undifferentiated or de-differentiated cells
transplanted is likely to be very small. These plasma
collection and imaging frequencies would be similar to
the sampling strategies employed in clinical trials to assess
functional changes following cardiovascular interventions,
which should simplify the adaption of such a monitoring
strategy to detect neoplastic growth or teratomas.
In summary, regenerative therapies based on PSC-derived
cells are rapidly evolving andmay finally fulfill their poten-
tial and lead to true tissue regeneration. Nonetheless, the
residual risk forneoplastic growthor teratoma formation re-
quires a sensitive monitoring strategy. Serum biomarkers
can detect most teratomas regardless of the organ in which
they reside, but immature teratomas might be missed. To
maximize the likelihood for detecting neoplastic growth
and teratoma formation, our study suggests that a combina-
tion of MRI focusing on high-risk organs with serum bio-
markers covering the entire bodywould be complementary.EXPERIMENTAL PROCEDURES
An expanded Experimental Procedures section is available in the
online Supplemental Information.
Generation of Human iPSCs and Differentiation to
Cardiomyocytes
Human iPSCs were generated using lentivirus- or Sendai virus-
based reprogramming vectors and were differentiated to cardio-
myocytes (see Supplemental Experimental Procedures).
Cryopreservation of CMs and Preparation for
Injection
Human ESC-CMs or iPSC-CMs were washed with PBS and de-
tached using TripleE (Gibco). Cells were pelleted at 200 3 g for
4 min, subsequently re-suspended in fetal bovine serum supple-
mented with 10% DMSO, and stored for 24 hr at 80C,
before transfer to liquid N2 for long-term storage. For injections,
1 3 107 viable CMs per animal were thawed briefly at 37C, re-
suspended in culture medium, and pelleted. Cell pellets were re-
suspended in 45 ml of PBS and transferred into 0.5-ml insulin
syringes with 28G needles.
Ischemia Reperfusion Injury and Cell Transplantation
All experimental protocols were approved by the Stanford
Research Ethics Committee. Ischemia reperfusion injury was
induced in 8- to 10-week-old male nude athymic rats (n = 65;
Charles River) by occluding the left anterior descending coronary
artery for 1 hr followed by reperfusion. Surgery was performed
aseptically under 1.5%–2% inhaled isoflurane anesthesia. Threethors
days later, MRI, ultrasound imaging, and plasma collection were
performed. One day after baseline imaging (day 4 after MI), a sec-
ond thoracotomy was performed and 1 3 107 human CMs or PBS
was injected at three sites around the scar area (15 ml per injection
site). The following cell and PBS injections were used for different
aspects of the study: (1) detection and teratoma growth, T-CMs
(n = 8); (2) alternative biomarkers, T-CMs (n = 8); (3) teratoma
detection via LGE, T-CMs (n = 16); (4) control for assessment of car-
diac function, PBS (n = 12); (5) changes in cardiac function due to
human CM engraftment, C1-CMs (n = 12); and (6) biomarker con-
trol group for stable human CM grafts, H7-CMs (n = 9).
Immunohistochemistry and Histological Methods
Immunofluorescence and histological analyses were performed us-
ing standard protocols.
In Vivo MRI
Cine, T1w, T2w, T2*w, and LGE images were acquired 1 day before
and 2, 4, 6, and 8 weeks after cell delivery using a 7-T MR901
Discovery horizontal bore scanner (Agilent Technologies). The
following imaging parameters were used for cardiac cine: fast
spoiled gradient echo, echo time (TE) 1.5 ms, repetition time
(TR) 6–8 ms, flip angle 15, slice thickness 1 mm, field of
view (FOV) 50 3 50 mm2, 20 images per R-R interval, matrix size
1923 192, and number of signal averages (NSA) 1. For the remain-
ing acquisitions, a slice thickness of 1mm, FOV403 40mm2 and a
matrix size of 1923 192 were used with the following imaging pa-
rameters: (1) for T1w acquisitions: spin echo, TE 9.7ms, TR 700ms,
and NSA 4; (2) for T2w acquisitions: spin echo, TE 20 ms, TR
700 ms, and NSA 4; (3) for T2*w acquisitions: spoiled gradient
echo, TE 7 ms, TR 10.3 ms, flip angle 20, and NSA 3; (4) and for
LGE: gradient echo inversion recovery, TE 1.4 ms, TR one breath-
ing interval, inversion time 280–370ms, flip angle 90, and NSA 2.
Ex Vivo MRI
Fixed hearts were embedded in 2% lowmelting point agarose and a
series of images with different inversion times, T2-weighting, and
T2*-weighting were acquired using a 30-mm diameter Millipede
volume coil (Agilent).
Ultrasound Imaging
B-mode ultrasound imaging was also performed using a Vevo 2100
ultrasound system (Visualsonics).
Quantification of Plasma Biomarkers
Two milliliters of blood were collected directly after each MRI ses-
sion via a tail vein catheter using EDTA-coated tubes. Blood was
stored on ice for up to 3 hr before centrifugation at 3000 3 g to
separate the plasma. Plasmawas aliquoted and stored at80Cun-
til specific ELISAs were performed. The following ELISA kits were
acquired and performed following the manufacturer’s protocols:
CEA (Abcam), AFP (R&D Systems), FGF (Invitrogen), HCG (Sigma),
vascular endothelial growth factor (Sigma), lactate dehydrogenase
(LDH; Abcam), alkaline phosphatase (ALP; Abcam), and CA-125
(Abcam). For the exploratory biomarker study, plasma from a sepa-
rate cohort of animals was used to screen for microRNAs or cancer-Stem Ceassociated proteins. Total RNA, including miRNA, was extracted
from plasma using an miRNeasy Serum/Plasma Kit (Qiagen) ac-
cording to the manufacturer’s protocol. Screening was performed
using the Human Cancer Pathway Finder miRNA PCR array
(Qiagen) according to the manufacturer’s protocol. The human
XL oncology array kit (R&D Systems) was used according to the
manufacturer’s protocol to screen for potential protein-based tera-
toma biomarkers.
Statistical Analysis
Results are shown as means ± SD. A regression analysis was per-
formed to test if a linear relation between the natural logarithm
of teratoma volume and time exists. A linear mixed effects model
was used to test for differences in cardiac function with fixed ef-
fects for functional parameter, cell group (teratoma or no cell
engraftment), time, and a random effect for individual rats. A
regression analysis was performed to test if a linear relationship
between plasma biomarker and teratoma volume exists. Four
parameter logistic curve fits were performed for absorbance
measured from standard dilutions to establish a standard curve
and calculate sample concentrations. Bland-Altman plots were
generated to compare teratoma volume estimates from different
MRI imaging sequences. Statistical analysis was performed using
R software version 2.8.1.
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